A clopidogrel-insensitive inducible pool of P2Y 12 receptors contributes to thrombus formation: Inhibition by elinogrel, a direct-acting, reversible P2Y 12 antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 54-61

  Haberstock Debic, Helena ^a   Andre, Patrick ^a   Mills, Scott ^a   Phillips, David R ^a   Conley, Pamela B ^a  

^a Portola Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CONVULXIN; CYCLIC AMP; DRUG METABOLITE; ELINOGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICAGRELOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTITHROMBOTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANIMALS; CYCLIC AMP; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR AGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUINAZOLINONES; RADIOLIGAND ASSAY; RECEPTORS, PURINERGIC P2Y12; SULFONAMIDES; THROMBOSIS; TICLOPIDINE;

EID: 80053138923     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184143     Document Type: Article

References (31)

1. André P, Deguzman F, Haberstock-Debic H, Mills S, Pak Y, Inagaki M, Pandey A, Hollenbach S, Phillips DR, and Conley PB (2011) Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding. J Pharmacol Exp Ther 338:22-30.
2. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, and Conley PB (2003a) P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112: 398-406. (Pubitemid 38063768)
3. André P, LaRocca T, Delaney SM, Lin PH, Vincent D, Sinha U, Conley PB, and Phillips DR (2003b) Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108:2697-2703. (Pubitemid 37466813)
4. Bal Dit Sollier C, Berge N, Boval B, Hovsepian L, and Drouet L (2009) Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 101:116-122.
5. Baurand A, Eckly A, Hechler B, Kauffenstein G, Galzi JL, Cazenave JP, Léon C, and Gachet C (2005) Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67:721-733. (Pubitemid 40365319)
6. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, and Valgimigli M (2011) Prospective evaluation of onclopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474-2483.
7. Gachet C (2001) ADP receptors of platelets and their inhibition. Thromb Haemost 86:222-232.
8. Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, and Tantry US (2010) The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 8:43-53.
9. Gurbel PA, Bliden KP, Hiatt BL, and O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-2913. (Pubitemid 36736631)
10. Gurbel PA and Tantry US (2006) Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 3:387-395. (Pubitemid 43978399)
11. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, and Mundell SJ (2005) P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 105:3552-3560. (Pubitemid 40628200)
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
13. Jantzen HM, Milstone DS, Gousset L, Conley PB, and Mortensen RM (2001) Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 108:477-483. (Pubitemid 32730794)
14. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, and Storey RF (2008) The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 19:125-133. (Pubitemid 351302377)
15. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, et al. (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160:65-72.
16. Lieu HD, Conley PB, Andre P, Leese PT, Romanko K, Phillips DR, Jurek M, Meloni A, Hutchaleelaha A, and Gretler DD (2007) Initial intravenous experience with PRT060128 (PRT128), on orally available, direct-acting, and reversible P2Y12 inhibitor. J Thromb Haemost 5 (Suppl 2):P-T-292 (abstract).
17. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527-533. (Pubitemid 32772726)
18. Mundell SJ, Barton JF, Mayo-Martin MB, Hardy AR, and Poole AW (2008) Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost 6:1393-1404. (Pubitemid 352022551)
19. Mundell SJ, Jones ML, Hardy AR, Barton JF, Beaucourt SM, Conley PB, and Poole AW (2006) Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 70:1132-1142. (Pubitemid 44268470)
20. Nurden P, Poujol C, and Nurden AT (1997) The evolution of megakaryocytes to platelets. Baillieres Clin Haematol 10:1-27. (Pubitemid 27192453)
21. Nurden P, Poujol C, Winckler J, Combrié R, Pousseau N, Conley PB, Levy-Toledano S, Habib A, and Nurden AT (2003) Immunolocalization of P2Y1 and TPalpha receptors in platelets showed a major pool associated with the membranes of alpha -granules and the open canalicular system. Blood 101:1400-1408. (Pubitemid 36182512)
22. Oestreich JH (2010) Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs 11:340-348.
23. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097-1105.
24. Quinn MJ, Murphy RT, Dooley M, Foley JB, and Fitzgerald DJ (2001) Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 297:496-500. (Pubitemid 32377977)
25. Savi P, Labouret C, Delesque N, Guette F, Lupker J, and Herbert JM (2001) P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283:379-383. (Pubitemid 32924702)
26. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, and Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896.
27. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, and Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251. (Pubitemid 40094733)
28. Shapiro MJ, Trejo J, Zeng D, and Coughlin SR (1996) Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonisttriggered versus tonic internalization and intracellular localization. J Biol Chem 271:32874-32880.
29. Ueno M, Rao SV, and Angiolillo DJ (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 6:445-453.
30. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057.
31. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, and Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502. (Pubitemid 32758501)